AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02613572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid
Study NCT02613572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00824694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Self-Monitoring Of Blood Glucose (SMBG)
Description: SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
Study NCT00824694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider Training
Description: Focused on normalizing the most significant glucose abnormalities at any given time.
Study NCT00824694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Focused on normalizing the most significant glucose abnormalities at any given time.
Study NCT00953121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and CPT-11 and Carboplatin
Description: Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
Study NCT00970294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion Program
Description: 10 week health promotion program 3-4 times per week
Study NCT03290300 — intervention group
Intervention type: DEVICE
Intervention: Vivaer Stylus
Description: Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
Study NCT02994147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-only control study medication is the same formulation as active treatment without active ingredient
Study NCT02994147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201CR
Description: The investigational product is formulated as controlled-release (CR) tablets
Study NCT00887419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Description: Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
Study NCT00887419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
Study NCT03431961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: 220 mcg administered twice daily for 14 days
Study NCT04360252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gracie Diet
Description: The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet.~The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest.
Study NCT04198181 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Resective surgery included lobectomy (partial or total brain lobe resection), tuberectomy (epileptogenic tuber resection), and tuberectomy plus (resection of epileptogenic tuber and perituberal gyri). Tuberectomy was typically performed on the epileptogenic tuber within or near an eloquent area. Lobectomy was performed in patients with large epileptogenic tubers in the brain lobes. Multiple lobectomies, tuberectomies, tuberectomies plus, and lobectomy combined with tuberectomy/tuberectomies plus were further performed in patients with multiple epileptogenic tubers.
Study NCT04472104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBCT-S
Description: Group mindfulness treatment for sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
Study NCT04472104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SexEd
Description: Group sex education on sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
Study NCT00745316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonapofylline
Description: Oral Tonapofylline - 2 capsules bid
Study NCT00745316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo - 2 capsules bid
Study NCT04372329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP4HealthySleep system
Description: Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy
Study NCT02397720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT02397720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02397720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given Orally
Study NCT02397720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02453282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Study NCT02453282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)+Tremelimumab
Study NCT02453282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Carboplatin
Description: Chemotherapy Agents
Study NCT02453282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Cisplatin
Description: Chemotherapy Agents
Study NCT02453282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Carboplatin
Description: Chemotherapy Agents
Study NCT02453282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + Cisplatin
Description: Chemotherapy Agents
Study NCT02453282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + Carboplatin
Description: Chemotherapy Agents
Study NCT02453282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study NCT02322775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks
Study NCT02322775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered subcutaneously every 4 weeks
Study NCT00923013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.
Study NCT00923013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.
Study NCT00923013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
Study NCT00923013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
Study NCT00870025 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: 200 IU, sc, every 5 days, 4 doses
Study NCT00870025 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: diluent, every 5 days, s.c., 4 doses
Study NCT00870025 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: diluent, every 5 days, s.c., 4 doses
Study NCT02431728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 5 mg capsule p.o. at bedtime daily
Study NCT02431728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: 5 mg capsule p.o. at bedtime daily
Study NCT05105009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: * Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~* Oral creatinine load using 5 grams of creatinine
Study NCT05105009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatinine Powder
Description: 5g of creatinine (Sigma) in 250 ml of water was taken orally
Study NCT05105009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 ml iohexol (Omnipaque) intravenously
Study NCT03524274 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
Study NCT03524274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03524274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT00255567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Stibogluconate
Description: Sodium Stibogluconate 20mg/kg/day for 30 days
Study NCT00255567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin sulphate
Description: Paromomycin sulphate
Study NCT00255567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSG and Paromomycin sulphate
Description: SSG and Paromomycin Sulphate 17 days
Study NCT03881540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDNA-MI group
Description: tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements and motivational interviewing counseling. .
Study NCT03881540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDNA-CC group
Description: tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements+ 150 min/week of moderate intensity exercise + and conventional counselling.
Study NCT03881540 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: UC group
Description: Meal plan of 1200-1500 kcal/day using conventional foods + 150 min/week of moderate intensity exercise + and conventional counselling
Study NCT04148430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100mg subcutaneous
Study NCT04019561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 high dose
Description: MEDI0382 high dose administered subcutaneously
Study NCT04019561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEDI0382 high dose
Description: Placebo for MEDI0382 high dose administered subcutaneously
Study NCT04019561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 low dose
Description: MEDI0382 low dose administered subcutaneously
Study NCT04019561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEDI0382 low dose
Description: Placebo for MEDI0382 low dose administered subcutaneously
Study NCT03116529 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Radiation, Immunotherapy, Surgery
Description: Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as >10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease.
Study NCT04610866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Investigational drug mitapivat (also known as AG-348, AGI-1480 and AGX-0841) is an orally bioavailable, broad-spectrum allosteric activator of alleles of the RBC-specific form of pyruvate kinase (PKR), as well as liver-type pyruvate kinase (PKL) and muscle pyruvate kinase (PKM1 and PKM2).
Study NCT02974647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT00717470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf®
Description: oral
Study NCT00717470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf®
Description: oral
Study NCT00717470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT01503086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies
Study NCT01503086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive Training
Description: Receive computer-assisted cognitive training
Study NCT01503086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Ancillary studies
Study NCT01503086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00717470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Description: oral
Study NCT00717470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone / prednisone
Description: oral
Study NCT01503086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04156906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D+ RH genotype matched red cell units for transfusion
Description: Chronically transfused patients with SCD and anti-D will receive D+ RH genotyped matched red cell units for transfusion in addition to standard C, E, and K antigen matching and being hemoglobin S negative, which is the Children's Hospital of Philadelphia institutional standard of care for patients with SCD. RH genotyping of donor units will be performed by the New York Blood Center (NYBC) Immunogenetics laboratory.
Study NCT03431961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 14 days
Study NCT01087502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1-4 mg daily after 12 weeks
Study NCT04426669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
Study NCT04426669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
Study NCT04426669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TIL)
Description: Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
Study NCT04426669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
Study NCT04194437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Liver System
Description: The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.
Study NCT03697577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT scans
Description: Patients will undergo CT or PETCT as part of standard of care
Study NCT03697577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA scan
Description: Patients will undergo DEXA scan to measure body fat mass (DEXA will be performed only if available)
Study NCT03367754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of Placebo given via intravenous (IV) infusion.
Study NCT03367754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (immunoglobulin \[Ig\] G4 kappa isotype) that binds to PD-1, thus blocking the receptor from binding with its ligands. Single dose of Pembrolizumab 200 mg given via intravenous (IV) infusion.
Study NCT01925781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine polacrilex
Description: 2 mg and 4 mg gum will be used according to the FDA approved product labelling
Study NCT01087502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
Study NCT01087502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
Study NCT01087502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo mach to 5 mg linagliptin once daily after 12 weeks
Study NCT01087502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 5 mg once daily
Study NCT01925781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAM 1100mAh CE4 eGo Clearomizer
Study NCT03149900 — intervention group
Intervention type: DRUG
Intervention: Secukinumab
Description: See Arm Description
Study NCT04038866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation gait with dual task
Study NCT04038866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation gait without dual task
Study NCT05438433 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets
Description: St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
Study NCT05438433 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets
Description: St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
Study NCT03027713 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: weaning protocol
Description: The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
Study NCT03470285 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multiparametric MR imaging (mpMRI)
Description: The main objective of the study is to assess the diagnostic accuracy of mpMRI in small renal tumors. The study characteristics will comply with recommended methods (Quadas, Stard). The population to be included will be representative of patients who would benefit from mpMRI if it is demonstrated to be accurate. In this project, the MR protocol will used the conventional MR sequences either on 1.5 or 3T systems and do not require development. Each center may use their own protocol as long as it includes the mandatory sequences.
Study NCT03606096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix IPV infant acellular Pertussis
Description: mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
Study NCT03606096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix IPV infant whole Pertussis
Description: mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
Study NCT03606096 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TT infant acellular Pertussis
Description: mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
Study NCT03606096 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TT infant whole Pertussis
Description: mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
Study NCT04636697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intramuscular injection
Description: Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)